• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Prescryptive to offer benefit coverage for Pear Therapeutics opioid use disorder treatments

April 2, 2021 By Sean Whooley

Pear Therapeutics Prescryptive HealthPear Therapeutics announced today that Prescryptive Health will offer and administer benefit coverage for its digital therapeutics.

Boston-based Pear Therapeutics’ reSET and reSET-O, two FDA-cleared prescription digital therapeutics (PDTs) for treating substance and opioid use disorder, have been added to Prescryptive’s formularies and are being administered as standard pharmacy benefits for its members, according to a news release.

Prescryptive is set to include reSET and reSET-O on its platform to offer a seamless experience for its members in using the PDTs, which provide algorithm-driven cognitive behavioral therapy, fluency training and contingency management.

reSET is a monotherapy for patients 18 years of age or older with substance use disorder, while reSET-O is used in combination with transmucosal buprenorphine for those 18 and up with opioid use disorder. Recent analysis highlighted the cost-effectiveness and quality of life improvements provided by reSET-O.

“Prescryptive has launched the world’s first health intelligence platform powered by blockchain that delivers patients the necessary prescription information they need in real-time to their mobile device while they are engaged with their healthcare provider,” Prescryptive CEO Chris Blackley said in the release. “Teaming with Pear to make reSET and reSET-O available to our members is a natural extension of our aim to deliver empowering benefit plan solutions that inspire better health.”

“With an aligned mission to engage patients and redefine the delivery of care, we are pleased to team with Prescryptive to provide people in recovery with covered access to innovative FDA-authorized treatments through their mobile devices when and where they need it most,” added Pear Therapeutics president & CEO Dr. Corey McCann. “With this coverage decision, Pear continues to expand access to PDTs by adding reSET and reSET-O to a standard formulary.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Patient Monitoring, Pharmaceuticals Tagged With: peartherapeutics, Prescryptive Health

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS